{"entity":{"id":"nct06948981","kind":"trial","name":"GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies","aka":[],"tldr":"A phase 1/2 trial of GT719 Injection in non-Hodgkin lymphoma, run by Grit Biotechnology, now recruiting.","summary":"GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies is a phase 1/2 interventional study registered as NCT06948981 by Grit Biotechnology, with 46 participants planned, started 2025-04-18 and due to reach its primary completion in 2028-04-17. Interventions recorded: GT719 Injection.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06948981","url":"https://clinicaltrials.gov/study/NCT06948981"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["non-hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06948981","phase":"1/2","setting":"A Single-arm, Open-label, Phase I/II Clinical Study of GT719 Injection for Recurrent/Refractory CD19 Positive Adult B-cell Malignancies","sponsor":"Grit Biotechnology","enrolled":46,"outcomes":[]},"route":"/trials/nct06948981/","neighbours":{"cancer":[{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}]}}